Novel ibuprofen prodrugs with improved pharmacokinetics and non-ulcerogenic potential
作者:Valmik D. Dhakane、Hemant V. Chavan、Vishnu N. Thakare、Laxman K. Adsul、Sadanand N. Shringare、Babasaheb P. Bandgar
DOI:10.1007/s00044-013-0639-8
日期:2014.1
anti-inflammatory activity with pharmacokinetic, ulcerogenic properties of various synthesized prodrugs of ibuprofen in experimental animals. Prodrugs 2, 6, 9, 10, 12, and 14 were found to possess significant anti-inflammatory activity with almost non-ulcerogenic potential than standard drug ibuprofen 1a in both normal and inflammation-induced rats. Metabolic stability of prodrugs 2, 6, 9, 10, 12, and 14 were
在本研究中,我们评估了布洛芬各种合成前药在实验动物中的抗炎活性和药代动力学,致溃疡性。发现在正常和炎症诱导的大鼠中,前药2、6、9、10、12和14具有比标准药物布洛芬1a显着的抗炎活性,几乎没有致溃疡的潜力。前药的代谢稳定性2,6,9,10,12,和14还对大鼠肝微粒体进行了研究,并通过估计在不同时间间隔下这些前药的曲线下面积(AUC)和血浆浓度来确定口服生物利用度。实验结果在第1和2小时引起较高的AUC和血浆浓度,表明与亲本布洛芬相比,口服生物利用度提高。发现这些前药具有最小的胃溃疡,并保留了在实验动物中观察到的抗炎活性。因此,目前的实验结果表明,抗炎药布洛芬酯前药的致溃疡潜力最小,各种药代动力学特性有了显着改善。